JP Morgan Maintains Overweight on Health Catalyst, Raises Price Target to $13
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Anne Samuel has maintained an Overweight rating on Health Catalyst (NASDAQ:HCAT) and raised the price target from $10 to $13.
September 04, 2024 | 10:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan has increased its price target for Health Catalyst from $10 to $13, maintaining an Overweight rating. This suggests a positive outlook for the stock.
The increase in price target from $10 to $13 by JP Morgan, along with maintaining an Overweight rating, indicates a positive sentiment from a major financial institution. This is likely to boost investor confidence and potentially lead to a short-term increase in HCAT's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100